MTOR and non-Hodgkin lymphoma: Aberrant BCR signaling pathways, including those involving the Src family kinases (Lyn, Syk), Akt/mTOR, Btk, NF-κB, observed in CLL and NHL [58,59] might also be implicated in NHL clinical resistance.